Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV): Samuel Isaly’s OrbiMed Advisors filed an amended 13D.
You can check out OrbiMed Advisors’ latest holdings and filings here.
Please follow OrbiMed Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings.
Follow Samuel Isaly's OrbiMed Advisors
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| OrbiMed Advisors | 0 | 3,919,600 | 0 | 3,919,600 | 3,919,600 | 14.6% |
| OrbiMed Capital GP V | 0 | 3,919,600 | 0 | 3,919,600 | 3,919,600 | 14.6% |
Follow Samuel Isaly's OrbiMed Advisors
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 6 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
NABRIVA THERAPEUTICS PLC
(Name of Issuer)
ORDINARY SHARES
(Title of Class of Securities)
62957M104
(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone: (212) 739-6400
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 24, 2018
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 6 – SEC Filing
SCHEDULE 13D
| CUSIP No. 62957M104 | ||||
| 1 | NAME OF REPORTING PERSONS OrbiMed Advisors LLC | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | |||
| 3 | SEC USE ONLY | |||
| 4 | SOURCE OF FUNDS (See Instructions) AF | |||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
| 8 | SHARED VOTING POWER 3,919,600 | |||
| 9 | SOLE DISPOSITIVE POWER 0 | |||
| 10 | SHARED DISPOSITIVE POWER 3,919,600 | |||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,919,600 | |||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.6%* | |||
| 14 | TYPE OF REPORTING PERSON (See Instructions) IA | |||
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 6 – SEC Filing
SCHEDULE 13D
| CUSIP No. 62957M104 | ||||
| 1 | NAME OF REPORTING PERSONS OrbiMed Capital GP V LLC | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | |||
| 3 | SEC USE ONLY | |||
| 4 | SOURCE OF FUNDS (See Instructions) AF | |||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
| 8 | SHARED VOTING POWER 3,919,600 | |||
| 9 | SOLE DISPOSITIVE POWER 0 | |||
| 10 | SHARED DISPOSITIVE POWER 3,919,600 | |||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,919,600 | |||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | o | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.6%* | |||
| 14 | TYPE OF REPORTING PERSON (See Instructions) OO | |||
____________
*This percentage is calculated based upon 36,691,490 of the Issuer’s Ordinary Shares (as defined below) outstanding, as set forth in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC (as defined below) on November 9, 2017.
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 6 – SEC Filing
SIGNATURE
After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: January 25, 2018
| OrbiMed Advisors LLC | ||||
| By: | /s/ Jonathan T. Silverman | |||
| Name: | Jonathan T. Silverman | |||
| Title: | Member of OrbiMed Advisors LLC | |||
| By: | /s/ Sven H. Borho | |||
| Name: | Sven H. Borho | |||
| Title: | Member of OrbiMed Advisors LLC | |||
| By: | /s/ Carl L. Gordon | |||
| Name: | Carl L. Gordon | |||
| Title: | Member of OrbiMed Advisors LLC | |||
| OrbiMed Capital GP V LLC | ||||
| By: | OrbiMed Advisors LLC its managing member | |||
| By: | /s/ Jonathan T. Silverman | |||
| Name: | /s/ Jonathan T. Silverman | |||
| Title: | Member of OrbiMed Advisors LLC | |||
| By: | /s/ Sven H. Borho | |||
| Name: | Sven H. Borho | |||
| Title: | Member of OrbiMed Advisors LLC | |||
| By: | /s/ Carl L. Gordon | |||
| Name: | Carl L. Gordon | |||
| Title: | Member of OrbiMed Advisors LLC | |||
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 6 – SEC Filing
Schedule II
The business and operations of OrbiMed Capital GP V LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth on Schedule I attached hereto.
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 6 – SEC Filing
EXHIBIT INDEX
| Exhibit | Description |
| 1. | Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP V LLC. |
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
Follow Nabriva Therapeutics Plc (NASDAQ:NBRV)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
